• If you are trying to work out whether BioCryst Pharmaceuticals at around US$6.38 is priced attractively or not, it helps to first separate the recent share price moves from the underlying value story.
• The stock has been under pressure recently, with returns of a 3% decline over the last 7 days, a 13.8% decline over the last 30 days, a 14.9% decline year to date, and a 26.8% decline over the last year. The 3 year and 5 year returns sit at 38.1% and 33.3% declines respectively.
• Recent news coverage around BioCryst has focused on its position within the broader pharmaceuticals and biotech space, and ongoing interest in how its product pipeline and funding profile might influence sentiment. This backdrop helps frame why some investors are reassessing both the risks and potential reward attached to the current share price.
• In this context, BioCryst scores 5 out of 6 on our valuation checks, indicating a valuation score of 5/6. Next we will look at how different methods such as multiples and discounted cash flows compare, before finishing with a more holistic way to think about what that valuation means for you.

Approach 1: BioCryst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model projects a company’s future cash flows and then discounts them back to today’s value, aiming to estimate what the business might be worth in total right now.

For BioCryst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow sits at about $47.7 million. Analysts provide explicit forecasts out to 2030, with projected free cash flow of $663.9 million in that year, and Simply Wall St extends those projections further using its own growth assumptions.

After discounting these projected cash flows back to today using the DCF method, the estimated intrinsic value works out to about $75.79 per share. Compared with the recent share price of roughly $6.38, this model implies the stock is about 91.6% undervalued based on these cash flow assumptions.

This result relies heavily on the cash flow forecasts and the discount rate used, so it should be one input rather than the only input in your assessment.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioCryst Pharmaceuticals is undervalued by 91.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: BioCryst Pharmaceuticals Price vs Sales

For companies where earnings are limited or volatile, the P/S ratio is often a more practical yardstick because it compares the company’s market value to its revenue rather than its profits. What investors are willing to pay per dollar of sales typically reflects their expectations for future growth and how risky they think those sales are.

BioCryst currently trades on a P/S of 2.64x. That sits below both the Biotechs industry average P/S of 11.15x and a peer group average of 17.17x. On the surface, that kind of gap can suggest either lower growth and higher perceived risk, or a potential valuation opportunity compared with other biotech names.

Simply Wall St’s Fair Ratio for BioCryst comes in at 5.08x. This is a proprietary estimate of what a “normal” P/S could be for the company, taking into account factors such as its earnings growth profile, industry, profit margins, market cap and specific risks. Because it adjusts for these elements, the Fair Ratio can be more tailored than a simple comparison with broad industry or peer averages. With the current 2.64x P/S sitting below the 5.08x Fair Ratio, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies.

Upgrade Your Decision Making: Choose your BioCryst Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which Simply Wall St hosts on its Community page used by millions of investors.

A Narrative is your story about a company, where you spell out what you think will happen to its revenue, earnings and margins in the future, and then connect that story to a clear fair value estimate.

Instead of only relying on a single DCF or multiple, a Narrative links three pieces together: the company story you believe, the financial forecast that follows from it, and the fair value that drops out of those numbers, which you can then compare with the current share price to help decide whether to buy, hold or sell.

Because Narratives on the platform update automatically when new information, such as earnings or news, is added, your view on BioCryst stays aligned with the latest data. You can see at a glance how one investor might see BioCryst as attractive at a higher fair value while another sets a much lower fair value based on more cautious assumptions.

Do you think there's more to the story for BioCryst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.